Literature DB >> 24037999

Minimizing over-diagnosis in lung cancer screening.

Frederic W Grannis1.   

Abstract

Overestimation of the frequency and impact of over-diagnosis bias in lung cancer screening has contributed to long delays in implementation of lung cancer screening programs. Literature review reveals little evidence of substantial numbers of over-diagnosed non-lethal lung cancer. There is now strong evidence that lung cancers that would not cause symptoms or kill during normal anticipated survival are uncommon and mostly limited to in situ adenocarcinomas, identifiable as CT non-solid nodules. Prevention of overtreatment is possible within well-constructed diagnostic algorithms.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  CT scan; computerized tomogram; in situ adenocarcinoma of the lung; lung cancer; lung cancer-specific mortality; non-lethal lung cancer; over-diagnosis; screening; survival; tumor volume doubling time

Mesh:

Year:  2013        PMID: 24037999     DOI: 10.1002/jso.23400

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  5 in total

1.  Lung cancer detection with digital chest tomosynthesis: first round results from the SOS observational study.

Authors:  Luca Bertolaccini; Andrea Viti; Chiara Tavella; Roberto Priotto; Donatella Ghirardo; Maurizio Grosso; Alberto Terzi
Journal:  Ann Transl Med       Date:  2015-04

Review 2.  Is there a role for IGF-1 in the development of second primary cancers?

Authors:  Thurkaa Shanmugalingam; Cecilia Bosco; Anne J Ridley; Mieke Van Hemelrijck
Journal:  Cancer Med       Date:  2016-10-13       Impact factor: 4.452

3.  Psychosocial consequences of false positives in the Danish Lung Cancer CT Screening Trial: a nested matched cohort study.

Authors:  Jakob Fraes Rasmussen; Volkert Siersma; Jessica Malmqvist; John Brodersen
Journal:  BMJ Open       Date:  2020-06-04       Impact factor: 2.692

4.  Assessment and model guided cancer screening promotion by village doctors in China: a randomized controlled trial protocol.

Authors:  Rui Feng; Xingrong Shen; Jing Chai; Penglai Chen; Jing Cheng; Han Liang; Ting Zhao; Rui Sha; Kaichun Li; Debin Wang
Journal:  BMC Cancer       Date:  2015-10-12       Impact factor: 4.430

Review 5.  Why and how would we implement a lung cancer screening program?

Authors:  Idris Guessous; Jacques Cornuz
Journal:  Public Health Rev       Date:  2015-11-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.